Fri.Dec 20, 2024

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Perhaps PD-1 inhibitors just arent for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.

186
186
article thumbnail

PM360 Presents the 2024 Innovators

PM360

Established in 2012, PM360 introduced the first-ever issue focused entirely on our industrys latest innovations. Categories explore every sector of the healthcare industry, from life sciences to marketing. PM360 would like to welcome you to the new age of innovation with our illuminating Innovations Issue. This yearly special issue has served as your go-to guide for the most interesting advancements in our industry over the past 13 years, by featuring a focussed view of 11 different areas in hea

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med developed by a Chinese company to win FDA approval. And more.

Pharma 174
article thumbnail

HUMANIZING HEALTHCARE – EXPERT on Call: CHANGING THE WAY HEALTH IS EXPERIENCED. The Culture-Forward Revolution

PM360

In the high-stakes world of healthcare, the relationship between pharmaceutical advertising and the people it aims to reach is at a critical crossroads. For far too long, underserved communities have seen little in these ads that speak to their lives let alone their unique healthcare journeys. Now more than ever, the industry is recognizing that diversity, equity, and inclusion (DEI) are not just add-ons, but essential elements that define successful, meaningful campaigns.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Thanks to a new FDA green light, Lillys dual GIP/GLP-1 blockbuster Zepbound has become the first prescription medicine cleared to treat adults with moderate-to-severe obstructive sleep apnea and obesity. The nod marks the second indication for Zepbound behind the inaugural obesity approval it scored in November 2023.

article thumbnail

Novo Nordisk takes a hit as CagriSema underperforms in weight loss

Pharmaceutical Technology

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

64

More Trending

article thumbnail

FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.

article thumbnail

Bristol Myers Squibb licenses amyloid-beta antibody programme

European Pharmaceutical Review

Bristol Myers Squibb has licensed an amyloid-beta antibody programme from BioArctic AB. The PyroGlutamate-amyloid-beta (PyroGlu-A) programme includes novel antibodies (BAN1503 and BAN2803). These target a truncated, pyroglutamate modified form of amyloid-beta. BAN2803 utilises a technology platform that optimises biologic drug delivery past the blood brain barrier, BioArctic noted.

article thumbnail

Astellas and Sangamo sign capsid deal for neurological diseases

Pharmaceutical Technology

Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

Pharma 64
article thumbnail

MedCity Pivot Podcast: Putting a Human Touch on Healthcare Navigation and Coordination

MedCity News

Heather Cox, President of Insights & Empowerment at Zelis, talked about the company’s care coordination tools with MedCity News Reporter Katie Adams. The post MedCity Pivot Podcast: Putting a Human Touch on Healthcare Navigation and Coordination appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA approves Ionis’ TRYNGOLZA for FCS treatment

Pharmaceutical Technology

The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS

FDA 59
article thumbnail

Startup Launches to Provide Geriatric Behavioral Health Support

MedCity News

Vitalic provides mental health support to older adults. It connects them to a care team that includes geriatric boarded psychiatrists, psychiatric nurse practitioners, licensed therapists and mental health support coaches. The post Startup Launches to Provide Geriatric Behavioral Health Support appeared first on MedCity News.

70
article thumbnail

10 of our most read articles of 2024

PharmaVoice

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

Pharma 59
article thumbnail

Palleon and Shanghai Henlius Biotech link on autoimmune therapy

Pharmaceutical Technology

Palleon and Henlius Biotech have entered into a licence agreement and partnership for the formers E-602 to treat autoimmune diseases.

59
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

How data-driven strategies can help improve patient retention

Clarify Health

Patient loyalty and satisfaction do more than enhance providers reputations and ratings: they can help encourage patients to stay with providers instead of seeking care elsewhere, a phenomenon known as patient leakage. Whether they choose a new provider on their own or are referred to one, losing patients can significantly impact providers revenue.

article thumbnail

Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025

Pharmaceutical Technology

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 20242028 VPAG.

article thumbnail

GUEST COMMENTARY: AI-Driven Remote Cardiac Monitoring: Managing Stress and Heart Health

PM360

Stressful scenarios trigger the bodys fightor-flight responsecausing the heart to race, blood pressure to spike, and stress hormones to flood the system. Stress responses have a biological purpose but can also produce unintended consequences when triggered chronically. Research shows stresss negative long-term effects 1 on healthincluding the cardiovascular system.

article thumbnail

Trade & Channel Strategies 2024: The Significance of Return on Invested Capital for Pharma Companies

Pharmaceutical Commerce

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations.

Pharma 52
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

The Cure for ‘Chronic Pilotitis’

PM360

Pilots are a go-to strategy of the pharmaceutical industry for getting new customer solutions into the marketplace. Most are still positioned at the periphery of the organizational operating model, with rigid definitions of success and failureminimizing their potential for lasting impact. As a result, there is a tendency to cut losses (and gains), moving quickly onto the next pilot.

Pharma 52
article thumbnail

Pharma Marketing's Top Movers and Shakers in 2024

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

Breaking Down Patient Access Barriers

PM360

After nearly five years of mounting pressures on the American healthcare system, providers and patients are confronting another challenge that shows no signs of slowing down: skyrocketing medical costs. Rising medical debt and high out-of-pocket expensesdriven in part by pharmaceutical price hikes, limited insurance coverage, shifts to high-deductible health plans, and the growing complexity of treatmentsplace an unprecedented burden on patients and providers.

article thumbnail

Peer Exchange: The Impact of RAIN RFID (Episode 5)

Pharmaceutical Commerce

In the fifth part of this roundtable discussion, subject matter experts discuss the role that various GS1 initiatives have played, and provide a breakdown of stakeholders who have benefitted greatly from RFID.

52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

DTC/ DTP 360 Operational Excellence: A Key to Biopharma Success

PM360

The last several years have been a unique period for the life sciences industry globally, marked by both unprecedented innovation and financial volatility. While biopharma companies continue to unlock powerful new therapeutic discoveries, sluggish funding and other challenges have forced players throughout the sector to seek new strategies to maintain momentum.

article thumbnail

LSPedia Opens New Office in Hyderabad, India

Pharmaceutical Commerce

As a result, the provider increases its involvement in the countrys pharma sector.

Pharma 52
article thumbnail

Clinical Trials Unintentionally Exclude Patients

PM360

Clinical trials can offer life saving treatments to patients in need. While most clinical trials fail to meet their intended endpoints, many succeed. However, not all people equally enjoy the opportunity to participate in clinical trials. Historically, racial and ethnic groups have been underrepresented in clinical trial studies. In 2020, the U.S. Food and Drug Administration reported that 75% of clinical trial subjects were white, while only 6% were Asian, 8% were Black, and 11% were Hispanic.

article thumbnail

Zepbound, Mounjaro shortages are resolved, FDA confirms

PharmaVoice

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

FDA 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Biologic Prices Decreasing As More Commercial Health Plans Allow Biosimilars as First-Line Options

PM360

When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. But the benefits of biosimilars were not immediate, as early biologics had slower acceptance and savings than expected.

article thumbnail

Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development

PharmaTech

In this episode of Drug Digest, industry experts discuss their experiences in dealing with the challenges of developing and manufacturing next-generation biotherapeutics as well as triumphs that move the industry as a whole forward.

article thumbnail

PM360 2024 Innovative STARTUPS: DxCheck.com

PM360

DxCheck Launched in 2023, DxCheck is an AI-powered digital health platform that has swiftly emerged as a leader in personalized patient engagement across rare diseases, chronic conditions, and oncology. By leveraging advanced open-source language models and curated data, DxCheck delivers tailored resources and medically reviewed content that resonate with patients specific health needs.

article thumbnail

Orexo and Abera Partner to Develop Nasal Powder Vaccines

PharmaTech

The companies will use Orexos powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A